The FDA is allowing C.R. Bard Inc. to change the primary endpoint to six months in the company's investigational device exemption (IDE) study for the Lutonix 014 drug-coated balloon (DCB) percutaneous transluminal angioplasty catheter. The modification comes as DCB technology stands out as a hot topic among interventional vascular and cardiology physicians this week at the annual VIVA meeting in Las Vegas.

Washington-based Danaher Corp. (NYSE: DHR) determined that buying molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) will boost its position in the molecular diagnostics space, but Danaher's investors may take more convincing.